Delayed emergence after remimazolam induction in end-stage liver disease. Comment on Br J Anaesth 2021; 127: 415-23

Affiliations

¹ Department of Anaesthesia and Perioperative Care, Rutgers New Jersey Medical School, Newark, NJ, USA.
² Department of Anaesthesia and Perioperative Care, Rutgers New Jersey Medical School, Newark, NJ, USA; Medical Corps, U.S. Army. Electronic address: naftalro@njms.rutgers.edu.

Free article

Comment

Amit Singal et al. Br J Anaesth. 2022 Dec.

Free article

. 2022 Dec;129(6):e171-e172.

doi: 10.1016/j.bja.2022.09.006. Epub 2022 Oct 5.

¹ Department of Anaesthesia and Perioperative Care, Rutgers New Jersey Medical School, Newark, NJ, USA.
² Department of Anaesthesia and Perioperative Care, Rutgers New Jersey Medical School, Newark, NJ, USA; Medical Corps, U.S. Army. Electronic address: naftalro@njms.rutgers.edu.

No abstract available

Keywords: delayed emergence; end-stage liver disease; general anaesthesia; hepatic metabolism; pharmacokinetics; remimazolam.

Comment on

Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment.
Stöhr T, Colin PJ, Ossig J, Pesic M, Borkett K, Winkle P, Struys MMRF, Schippers F. Stöhr T, et al. Br J Anaesth. 2021 Sep;127(3):415-423. doi: 10.1016/j.bja.2021.05.027. Epub 2021 Jul 8. Br J Anaesth. 2021. PMID: 34246461 Clinical Trial.